NEW YORK – San Francisco-based Atara Biotherapeutics said on Monday that the US Food and Drug Administration has accepted its investigational new drug application for ATA2271, a mesothelin-targeting autologous CAR T-cell therapy that it is developing for the treatment of advanced mesothelioma.
The IND clearance enables Atara to begin a single-arm, Phase I trial in this indication for ATA2271, which the company developed in collaboration with Memorial Sloan Kettering.